BAX602 in Preventing the Adhesion Around Great Cardiac Vessels in Pediatric Patients With Congenital Heart Disease Undergoing Re-do Open Heart Surgery (Japan Trial)

NCT05647161 | Active Not Recruiting FDA Device

• 1 other identifier: BAX602-PED
• Study Type: interventional
• Target: 34
• Locations: 1 country
• Sites: 6

Brief Summary

Congenital heart disease occurs in about 1% of live births and can range from (1) naturally curable conditions that require no treatment to (2) conditions that require multiple immediate operations or refractory severe conditions. In the course of a staged surgical intervention, adhesion formation around the heart and large vessels can occur, and dissection of the adhesion site is required at the time of reoperation. There is a concern that dissection may markedly increase the risk of operation such as prolonged surgical time, cardiovascular injury, and increased blood loss, and medical devices to prevent adhesion formation after operation in the field of pediatric cardiovascular operation are strongly desired in medical settings. The investigational product (BAX602), which has already been manufactured and marketed by Baxter overseas, has been used for open heart surgery as a local hemostatic agent without biological materials in Europe and the US for more than 20 years. However, since it has not been approved in Japan, this randomized controlled study will be conducted in Japan to demonstrate the effect of BAX602 to prevent and reduce adhesion formation between the surface of the heart/large vessels and surrounding tissues in pediatric patients undergoing planned multistage operation for congenital heart disease.

Conditions

Congenital Heart Disease in Children

Keywords

open heart surgery; anti-adhesion

Outcome Measures

Primary Outcomes (1)

• Grade of adhesion between the surface of the heart/large vessels and surrounding tissues

  The following score of adhesion grade will be used: Grade 0=No adhesions; Grade 1=Filmy and avascular; Grade 3=Filmy, noncohesive requiring blunt and sharp dissection; Grade 4=Dense and cohesive requiring extensive sharp dissection. Lower score is better outcome.

  Day 90 to Day 360 (2nd open heart surgery)

Secondary Outcomes (10)

• Total surgery time

  Day 90 to Day 360 (2nd open heart surgery)

• Time from start of skin incision to start of extracorporeal circulation

  Day 90 to Day 360 (2nd open heart surgery)

• Time from start of skin incision to the end of adhesion dissection

  Day 90 to Day 360 (2nd open heart surgery)

• Total score of grade of adhesion at evaluation sites

  Day 90 to Day 360 (2nd open heart surgery)

• Grade of adhesion by evaluation site and presence or absence of extracorporeal circulation

  Day 90 to Day 360 (2nd open heart surgery)

Study Arms (2)

Treatment Group

EXPERIMENTAL

Participants undergo 1st open heart surgery (first operation), and before closing the chest BAX602 will be sprayed on the surface of the heart and large vessels. Efficacy will be evaluated via adhesiolysis after re-do (2nd) open heart surgery. Re-do open (2nd) heart surgery will be performed ≥3 month (90 days) to ≤12 months (360 days) after 1st open heart surgery. If the re-do open heart surgery is performed later than 12 months (360 days) after the 1st open heart surgery, serious adverse events should be collected until the end of the clinical trial (at the time of discharge after re-do surgery), all observations and endpoints will be collected, including primary endpoints, items related to secondary endpoints, safety endpoints, and other observational items whenever possible. The participants will be observed for safety up to discharge after re-do open heart surgery (up to 30 days).

Device: BAX602

Non-Treatment Group

ACTIVE COMPARATOR

Participants undergo 1st open heart surgery (first operation) and the chest will be closed without spraying BAX602. Efficacy will be evaluated via adhesiolysis after re-do (2nd) open heart surgery. Re-do open (2nd) heart surgery will be performed ≥3 month (90 days) to ≤12 months (360 days) after 1st open heart surgery. If the re-do open heart surgery is performed later than 12 months (360 days) after the 1st open heart surgery, serious adverse events should be collected until the end of the clinical trial (at the time of discharge after re-do surgery), all observations and endpoints will be collected, including primary endpoints, items related to secondary endpoints, safety endpoints, and other observational items whenever possible. The participants will be observed for safety up to discharge after re-do open heart surgery (up to 30 days).

Device: No Intervention

Interventions

BAX602 DEVICE

Consists of the spray agent, spray set, and spraying device (regulator). Dissolves a polyethylene glycol (PEG) derivative with an N-hydroxysuccinimide group at the end (COH102) and a PEG derivative with a thiol group (COH206) as an anti-adhesion agent, which is sprayed on the surgical surface to reduce the degree, frequency, and extent of organ adhesions after surgery.

Treatment Group

No Intervention DEVICE

Control Group

Non-Treatment Group

Eligibility Criteria

• Age: 0 Years - 12 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• Patients \<12 years of age
• Patients who have undergone the first scheduled palliative surgery for the following diseases and are scheduled to undergo re-do open heart surgery (anatomical repair surgery):
• Ventricular septal defect
• Atrioventricular septal defect
• Tetralogy of Fallot (spectrum)

You may not qualify if:

• Patients who will undergo BT shunting or pulmonary artery banding (including bilateral pulmonary artery banding) for the first surgery
• Patients undergoing repair surgery (anatomical repair surgery) or bi-directional Glenn surgery as the second target procedure
• Patients for whom written consent has been obtained from the patient or a surrogate
• Patients with hypoplastic left heart syndrome (HLHS) and its analogues.
• Patients with asplenia or hypersplenism.
• Patients undergoing Norwood surgery as the second surgery.
• Patients undergoing open heart surgery prior to the first scheduled palliative surgery.
• Patients with complications of other organs that affect the indication for cardiac surgery.
• Patients with chromosomal or genetic abnormalities that may affect the indication for cardiac surgery.
• Patients with severe infections or multiple organ failure.
• Patients who require emergency surgery that requires emergency life support.
• Patients' body weight is less than 2,500g at birth.
• Patients who are participating in other clinical trials or who are scheduled to participate in other clinical trials during this study period.
• Patients who are judged by the investigator or sub investigator to be inappropriate to participate in this study for other reasons.

Sponsors & Collaborators

• Baxter Healthcare Corporation: lead

Study Sites (6)

Aichi Children's Hospital and Medical Center

Ōbu, Aichi-ken, 474-8710, Japan

Location

Fukuoka Children's Hospital

Fukuoka, Fukuoka, 813-0017, Japan

Location

Hyogo Prefectural Kobe Children's Hospital

Kobe, Hyōgo, 6500047, Japan

Location

Nagano Children's Hospital

Azumino, Nagano, 3998288, Japan

Location

Okayama University Hospital

Okayama, Okayama-ken, 700-8558, Japan

Location

Shizuoka Children's Hospital

Shizuoka, Shizuoka, 420-8660, Japan

Location

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 18, 2022
• First Posted: December 12, 2022
• Study Start: December 8, 2022
• Primary Completion: October 31, 2025
• Study Completion: December 31, 2025
• Last Updated: July 22, 2024

Record last verified: 2024-07

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, CSR
• Time Frame: Upon approval of a legitimate research request.
• Access Criteria: Research requests will be reviewed by qualified medical and scientific experts within the company. If Baxter agrees to the release of clinical data for research purposes, the requestor will be required to sign a data sharing agreement (DSA) in order to ensure protection of patient confidentiality and any intellectual property rights of Baxter prior to the release of any data.

Locations

JP (6)